全文获取类型
收费全文 | 408篇 |
免费 | 43篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 15篇 |
妇产科学 | 8篇 |
基础医学 | 53篇 |
口腔科学 | 9篇 |
临床医学 | 42篇 |
内科学 | 80篇 |
皮肤病学 | 63篇 |
神经病学 | 38篇 |
特种医学 | 6篇 |
外科学 | 28篇 |
综合类 | 6篇 |
预防医学 | 36篇 |
眼科学 | 15篇 |
药学 | 28篇 |
中国医学 | 1篇 |
肿瘤学 | 25篇 |
出版年
2024年 | 4篇 |
2023年 | 14篇 |
2022年 | 16篇 |
2021年 | 29篇 |
2020年 | 23篇 |
2019年 | 21篇 |
2018年 | 30篇 |
2017年 | 17篇 |
2016年 | 26篇 |
2015年 | 24篇 |
2014年 | 32篇 |
2013年 | 28篇 |
2012年 | 36篇 |
2011年 | 44篇 |
2010年 | 28篇 |
2009年 | 12篇 |
2008年 | 5篇 |
2007年 | 13篇 |
2006年 | 6篇 |
2005年 | 3篇 |
2004年 | 6篇 |
2003年 | 6篇 |
2002年 | 6篇 |
2001年 | 3篇 |
2000年 | 2篇 |
1999年 | 2篇 |
1998年 | 1篇 |
1997年 | 3篇 |
1996年 | 3篇 |
1995年 | 2篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1990年 | 5篇 |
1981年 | 2篇 |
1979年 | 1篇 |
1977年 | 1篇 |
1975年 | 1篇 |
1974年 | 1篇 |
1973年 | 1篇 |
排序方式: 共有459条查询结果,搜索用时 15 毫秒
31.
32.
M Pini C Pattachini R Quintavalla T Poli A Megha A Tagliaferri C Manotti A G Dettori 《Thrombosis and haemostasis》1990,64(2):222-226
271 patients with acute symptomatic deep venous thrombosis of lower limbs, confirmed by strain-gauge plethysmography and/or venography, were randomly assigned to receive intermittent subcutaneous heparin calcium or heparin sodium by continuous intravenous infusion for 6-10 days. Heparin dosage was adjusted to maintain activated partial thromboplastin time values (Thrombofax reagent) at 1.3-1.9 times the basal ones. Strain-gauge plethysmography was repeated at the end of heparin treatment, and evaluation of therapy was performed by comparing the indexes of venous hemodynamics and by assessing the incidence of pulmonary embolism and of bleeding complications. In the intravenous group, Maximal Venous Outflow (MVO) increased from 20.8 +/- 12.8 to 28.4 +/- 17.5 ml/min per 100 ml of tissue and Venous Capacitance (VC) from 1.39 +/- 0.92 to 1.94 +/- 1.0 ml/100 ml of tissue (mean +/- SD). In the subcutaneous group, MVO increased from 21.0 +/- 12.7 to 27.5 +/- 18.1 and VC from 1.60 +/- 0.86 to 2.06 +/- 1.0. The median improvement of MVO and VC were 22% and 36% respectively in the IV group and 20% and 24% in the SC group. Clinical pulmonary embolism occurred in 2 patients in the intravenous group (1 fatal) and in 4 in the subcutaneous group (1 fatal). 9 major bleeding complications occurred in the intravenous group (1 fatal) and 5 in the subcutaneous group (1 fatal). The differences were not significant at the statistical analysis. The results suggest that subcutaneous intermittent heparin has a comparable efficacy to continuous intravenous heparin in the treatment of deep venous thrombosis. To the same conclusion points an overview of the seven randomized trials which compared these treatment modalities. 相似文献
33.
Yerem Yeghiazarians Muhammad Khan Franca S. Angeli Yan Zhang Sarah Jahn Megha Prasad Rachel Mirsky Henry Shih Petros Minasi Andrew Boyle William Grossman 《Journal of cardiac failure》2010,16(8):669-678
BackgroundErythropoietin (EPO) and granulocyte colony stimulating factor (GCSF) are potential novel therapies after myocardial infarction (MI). We first established the optimal and clinically applicable dosages of these drugs in mobilizing hematopoietic stem cells (HSC), and then tested the efficacy of monotherapy and combination therapy post-MI.Methods and ResultsOptimal doses were established in enhanced green fluorescent protein (eGFP) + chimeric mice (n = 30). Next, mice underwent MI and randomized into 4 groups (n = 18/group): 1) GCSF; 2) EPO; 3) EPO+GCSF; and 4) control. Left ventricular (LV) function was analyzed pre-MI, at 4 hours and at 28 days post-MI. Histological assessment of infarct size, blood vessels, apoptotic cardiomyocytes, and engraftment of eGFP+ mobilized cells were analyzed at day 28. LV function in the control group continued to deteriorate, whereas all treatments showed stabilization. The treatment groups resulted in less scarring, increased numbers of mobilized cells to the infarct border zone (BZ), and a reduction in the number of apoptotic cardiomyocytes. Both EPO groups had significantly more capillaries and arterioles at the BZ.ConclusionWe have established the optimal doses for EPO and GCSF in mobilizing HSC from the bone marrow and demonstrated that therapy with these agents, either as monotherapy or combination therapy, led to improvement of cardiac function post-MI. Combination therapy does not seem to have additive benefit over monotherapy in this model. 相似文献
34.
T. Roshni Paul Shantveer G. Uppin Megha S. Uppin Rachel T. Jacob D. Raghunadha Rao Senthil J. Rajappa 《Indian journal of hematology & blood transfusion》2010,26(2):56-61
Imatinib Mesylate, a Tyrosine Kinase inhibitor, is presently the drug of choice for Chronic myeloid leukemia (CML). During
therapy, a few patients develop myelosuppression and present with cytopenias. To study the bone marrow morphology in imatinib
treated CML patients presenting with persistent cytopenias. The cases were retrieved from the Hematopathology record files,
Department of Pathology; the study period being January 2008–June 2009. Cases of CML on Imatinib presenting with grade 2 or
more anemia, neutropenia and/or thrombocytopenias with bone marrow studies, were included in the study. The morphology of
all cases was reviewed with cytogenetic studies. Follow-up details were obtained from the Medical Oncology records. During
the study period, 683 Imatinib treated CML patients had bone marrow studies as part of their follow-up investigations. Of
these, 60 patients (9%) had some form of persistent cytopenia. The patients ranged from 21 to 75 years of age with a median
age of 38 years. The male:female ratio was 1:1. There were 46 patients with ≥grade 2 anemia, 25 patients with ≥grade 2 neutropenia
and 37 patients with ≥grade 2 thrombocytopenia. Of these, 18 patients had bicytopenia and 13 cases had pancytopenia. The marrow
evaluation revealed morphologic response in 30 patients, persistent marrow disease in five patients, marrow hypoplasia in
six patients, extensive stromal changes including fibrosis in five patients, megaloblastic erythropoiesis in 11 patients and
disease progression to accelerated or blast crisis in three patients. Various degrees of cytopenias may occur in few patients
of CML on imatinib therapy. Regular hematologic follow-up is required so that the drug may be stopped or dose modified as
per the individual’s needs. 相似文献
35.
Megha S. Uppin Liza Rajasekhar H. Swetha V. R. Srinivasan Aruna K. Prayaga 《Clinical rheumatology》2010,29(7):815-818
Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disorder. Renal involvement has the worst prognosis. However,
renal cortical necrosis is extremely unusual in SLE. In this case report, we describe the autopsy findings in a young female
patient with SLE presenting with renal failure. At autopsy, there was Libmann–Sacks endocarditis with multiorgan infarcts
and renal cortical necrosis. Secondary antiphospholipid antibodies contribute to the cardiac and renal manifestations in SLE.
We discuss the incidence and pathogenesis of endocarditis with differential diagnosis for cortical necrosis in a patient of
SLE. 相似文献
36.
37.
Shin S Ku YH Ho JX Kim YK Suh JS Singh M 《Clinical hemorheology and microcirculation》2007,36(3):253-261
The erythrocyte deformability of blood samples, of diabetes mellitus (DM) patients with and without microangiopathic complications such as nephropathy and retinopathy, is determined and is compared with that of healthy control. The erythrocyte deformability is measured in terms of elongation index (EI) with microfluidic ektacytometer, which is very sensitive to detect changes in EI of erythrocytes due to hyperglycemic process. Each measurement of diffraction pattern of erythrocyte suspension in a highly viscous polyvinyl pyrroridone (PVP) solution in a disposable microchannel is carried out. The results show that EI is well correlated with the levels of glycated hemoglobin and creatinine, as determined from the blood samples of patients. A significant decrease in the EI in DM patients compared with that in normal control is observed. In patients with complications of chronic renal failure, end stage renal disease, retinopathy and with combination of retinopathy and nephropathy, the EI is significantly decreased in comparison with that of diabetes patients without these complications. Further reduction in EI is corresponded to the changes induced by the microangiopathy process despite the maintenance of blood glucose and glycated hemoglobin by drug therapy. 相似文献
38.
Gaps in the knowledge about advancements in rabies vaccines among the undergraduate medical students
Enormous developments have taken place during the past few years in the field of Rabies prevention and control particularly rabies vaccines. Intra-dermal Rabies Vaccination (IDRV) has already emerged as a safe, ethical and cost-effective replacement. However appropriate dissemination of knowledge and implementation by medical fraternity is imperative for effective prevention and control of this fatal disease. Gaps were found in the knowledge of medical students regarding the newer rabies vaccines. This can be resolved to great extent by updating the undergraduate curriculum with the current control strategies used in this field. 相似文献
39.
Thalidomide attenuates nitric oxide-driven angiogenesis by interacting with soluble guanylyl cyclase
Syamantak Majumder Megha Rajaram Ajit Muley Himabindu S Reddy KP Tamilarasan Gopi Krishna Kolluru Swaraj Sinha Jamila H Siamwala Ravi Gupta R Ilavarasan S Venkataraman KC Sivakumar Sharmila Anishetty Pradeep G Kumar Suvro Chatterjee 《British journal of pharmacology》2009,158(7):1720-1734
Background and purpose:
Nitric oxide (NO) promotes angiogenesis by activating endothelial cells. Thalidomide arrests angiogenesis by interacting with the NO pathway, but its putative targets are not known. Here, we have attempted to identify these targets.Experimental approach:
Cell-based angiogenesis assays (wound healing of monolayers and tube formation in ECV304, EAhy926 and bovine arterial endothelial cells), along with ex vivo and in vivo angiogenesis assays, were used to explore interactions between thalidomide and NO. We also carried out in silico homology modelling and docking studies to elucidate possible molecular interactions of thalidomide and soluble guanylyl cyclase (sGC).Key results:
Thalidomide inhibited pro-angiogenic functions in endothelial cell cultures, whereas 8-bromo-cGMP, sildenafil (a phosphodiesterase inhibitor) or a NO donor [sodium nitroprusside (SNP)] increased these functions. The inhibitory effects of thalidomide were reversed by adding 8-bromo-cGMP or sildenafil, but not by SNP. Immunoassays showed a concentration-dependent decrease of cGMP in endothelial cells with thalidomide, without affecting the expression level of sGC protein. These results suggested that thalidomide inhibited the activity of sGC. Molecular modelling and docking experiments revealed that thalidomide could interact with the catalytic domain of sGC, which would explain the inhibitory effects of thalidomide on NO-dependent angiogenesis.Conclusion and implications:
Our results showed that thalidomide interacted with sGC, suppressing cGMP levels in endothelial cells, thus exerting its anti-angiogenic effects. These results could lead to the formulation of thalidomide-based drugs to curb angiogenesis by targeting sGC. 相似文献40.
Uppin MS Sundaram C Meena AK Reddy KM Reddy KK Vanniarajan A Thangaraj K 《Neurology India》2008,56(3):391-393
We describe the clinical presentation, course and pathologic findings found in three adult patients with lipid storage myopathy. Excessive lipid storage was found in Type 1 fibers of muscle. Clinical improvement on oral levo-carnitine therapy suggests the possibility of carnitine deficiency as the most likely etiology in two of the patients and one had mitochondrial myopathy confirmed on genetic analysis. 相似文献